Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: The LEAP-study

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Verschuur, Constant V M ^a   Suwijn, S R ^a   Post, B ^b   Dijkgraaf, M ^c   Bloem, B R ^b   van Hilten, J J ^d   van Laar, T ^e   Tissingh, G ^f   Deuschl, G ^g   Lang, A E ^h   de Haan, R J ^c   de Bie, R M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f Zuyderland Medical Centre   (Netherlands)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Disease modifying; Levodopa; Parkinson's disease; Randomised delayed start placebo controlled trial

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; PLACEBO; ANTIPARKINSON AGENT; CARBIDOPA; DRUG COMBINATION;

ADULT; AMC LINEAR DISABILITY SCORE; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; EUROPEAN QUALITY OF LIFE 5 DIMENSION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE 39; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; NETHERLANDS; TIME TO TREATMENT;

ANTIPARKINSON AGENTS; CARBIDOPA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HUMANS; LEVODOPA; NETHERLANDS; PARKINSON DISEASE; QUALITY OF LIFE; TIME-TO-TREATMENT;

EID: 84947800128     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0491-1     Document Type: Article

References (25)

1. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008;359(23):2468-76.
2. Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-205.
3. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508.
4. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21(4):343-54.
5. Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology. 2011;77(15):1416-7.
6. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83.
7. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6-23.
8. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn SMC, Calne DB, editors. Recent developments in Parkinson's disease, vol. Volume 2. Florham Park: Macmillan Healthcare Information; 1987. p. 153-63. 293-304.
9. Weisscher N, Post B, de Haan RJ, Glas CA, Speelman JD, Vermeulen M. The AMC Linear Disability Score in patients with newly diagnosed Parkinson disease. Neurology. 2007;69(23):2155-61.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
11. Inoue T, Kitagawa M, Tanaka T, Nakagawa S, Koyama T. Depression and major depressive disorder in patients with Parkinson's disease. Mov Disord. 2010;25(1):44-9.
12. Marinus J, Visser M, Jenkinson C, Stiggelbout AM. Evaluation of the Dutch version of the Parkinson's Disease Questionnaire 39. Parkinsonism Relat Disord. 2008;14(1):24-7.
13. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69(1):67-73.
14. Hakkaart-van Roijen L, Bouwmans CAM. Handleiding Short Form- Health and Labour Questionnaire (SF-HLQ). Rotterdam: iMTA, Erasmus Universiteit; 2010.
15. van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405-15.
16. Hoefman RJ, van Exel NJA, Brouwer WBF. iMTA Valuation of Informal Care Questionnaire (iVICQ). Version 1.0 (December 2011). Rotterdam: iBMG / iMTA; 2011 [retrieved from www.bmg.eur.nl/english/imta/ivicq/documents/ on 14/10/2015].
17. Hakkaart-van Roijen L, Essink Bot ML. Handleiding Vragenlijst over Ziekte en Werk. Rotterdam: Erasmus University/ Institute for Medical Technology Assessment; 1999.
18. van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62(4):835-45.
19. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78.
20. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol. 2010;67(1):64-70.
21. D'Agostino Sr RB. The delayed-start study design. N Engl J Med. 2009;361(13):1304-6.
22. Velseboer DC, Broeders M, Post B, van Geloven N, Speelman JD, Schmand B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013;80(7):627-33.
23. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2010;16(8):490-7.
24. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013;28(8):1064-71.
25. Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731-42.